Antibacterial

Indication for use
Treatment of mild to moderate infections caused by susceptible microorganisms
Adults and adolescents
Community-acquired pneumonia, caused by:
- Haemophilus influenzaе (including beta-lactamase producing strains)
- Haemophilus parainfluenzae (including beta-lactamase producing strains)
- Streptococcus pneumonia (sensitive to penicillin strains only)
- Moraxella catarrhalis (including beta-lactamase producing strains)
Acute Chronic Bronchitis Exacerbation, caused by:
- Haemophilus influenza (including beta-lactamase producing strains)
- Haemophilus parainfluenzae (including beta-lactamase producing strains)
- Streptococcus pneumoniae (sensitive to penicillin strains only)
- Moraxella catarrhalis (including beta-lactamase producing strains)
Acute maxillary sinusitis, caused by:
- Haemophilus influenza (including beta-lactamase producing strains)
- Streptococcus pneumonia (sensitive to penicillin strains only)
- Moraxella catarrhalis (including beta-lactamase producing strains)
Pharyngitis/tonsillitis
- Streptococcus pyogenes
Uncomplicated skin and skin tissue infections, caused by:
- Staphylococcus aureus (including beta-lactamase producing strains)
- Streptococcus pyogenes

Treatment of mixed etiology infections caused by microorganisms and protozoa susceptible to combination of ciprofloxacin + ornidazole:

- infectious and inflammatory diseases of genitourinary organs;

- intestinal infections.

It is necessary to take into account the current official guidelines on the rules of antibacterial agents administration.

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug.
- tonsillopharyngitis caused by beta-hemolytic streptococcus A (as an alternative to beta-lactam antibiotic treatment, especially in case of contraindications to the above);
- acute sinusitis (Doramycin-Reb is indicated in case of contraindications to beta-lactam antibiotics);
- acute bronchitis and chronic bronchitis exacerbation;
- community-acquired pneumonia in patients without adverse outcome risk factors, severe clinical symptoms and clinical signs of pneumococcal etiology pneumonia;
- pneumonia caused by atypical pathogens (such as Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella spp.);
- skin and subcutaneous tissue infections, including impetigo, ecthyma, infectious dermohypodermatitis (especially, erysipelas), secondary infected dermatoses, erythrasma;
- oral infections (including stomatitis, glossitis);
- non-gonococcal genital infections;
- toxoplasmosis, including that of pregnancy;
- musculoskeletal system and connective tissue (including periodontium) infections;
- prevention of rheumatism recurrence in patients allergic to beta-lactam antibiotics;
- eradication of Neisseria meningitidis in nasopharynx (in case of contraindications to rifampicin) for prevention (but not treatment) of meningococcal meningitis.

Cefamed-Reb is indicated for treatment of the following infections in adults and children from birth:

- bacterial meningitis;

- community-acquired pneumonia;

- hospital-acquired pneumonia;

- acute otitis media;

- intra-abdominal infections;

- complicated urinary tract infections (including pyelonephritis);

- bone and joint infections;

- complicated skin and soft tissue infections;

- gonorrhea;

- syphilis;

- bacterial endocarditis.

Cefamed-Reb can be used for:

- treatment of chronic obstructive pulmonary disease exacerbation in adults;

- treatment of Lyme borreliosis (in early (stage II) and late (stage III) periods of the disease) in adults and children, including newborns - 15 days old;

- preoperative prevention of surgical infections;

- treatment of bacterial etiology neutropenic fever;

- treatment of bacteremia caused or presumably caused by any of the above mentioned infections.

Infectious and inflammatory diseases (in patients over 18 years old) caused by microorganisms sensitive to moxifloxacin.

Acute bacterial otitis media caused by:

Haemophilus influenza (including beta-lactamase producing strains)
Streptococcus pneumonia (penicillin-susceptible strains only)
Moraxella catarrhalis (including beta-lactamase producing strains)